SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalNNVC - NanoViricides, Inc.


Previous 10 Next 10 
To: donpat who wrote (6881)6/6/2016 4:14:56 PM
From: drkaz
   of 12856
 
Mostly just summarizing what those of us paying attention already know, and trying to put it into something resembling perspective.

Nothing special.

YW donpat.

Share RecommendKeepReplyMark as Last Read


From: donpat6/6/2016 4:45:05 PM
   of 12856
 
The time for action on Zika virus is now

June 06, 2016, 12:16 pm

By Sen. Bill Nelson (D-Fla.)

When Congress reconvenes this week, its first priority must be Zika.

Before the Senate adjourned for Memorial Day, I asked Senate Majority Leader Mitch McConnell to keep the Senate in session to deal with Zika. He did not.

Since then, more Americans have been infected with the virus and the first baby with Zika-linked microcephly was born in the continental U.S.

It's been more than three months since the president requested $1.9 billion in emergency funding to curb the spread of the this virus here in the U.S., yet Congress as a whole still hasn't acted. When the president made that request, there were just 50 confirmed cases of Zika in the U.S. Today, there are more than 1,500.

As public health officials around the world work to better understand this virus and how to stop it, there’s one thing we know for sure: time is of the essence.

And despite news that the House and Senate both successfully advanced measures last month aimed at funding the fight against Zika, Congress has not yet provided one dollar of the $1.9 billion the president says he needs to protect the American people.

While the Senate has approved a measure that would provide $1.1 billion and the House has passed a proposal of its own to provide $622 million, neither of these two funding measures are likely to become law.

That’s because the Senate’s proposal is tied to a larger spending bill that will likely be the subject of a rather lengthy negotiation between the two chambers, and the House plan has already drawn fire from the White House who’s said it will likely veto the measure should it ever make it to the president's desk.

So it's clear that the only way to get Congress to approve a plan that the president will sign is for the Senate to restart the process this week by passing a stand-alone bill and sending it to the House for consideration.

I have tried time and time again to get the Senate to do just that. Yet, every time I do, a Republican senator blocks the attempt. Sen. Marco Rubio (R-Fla.) and I even joined together to offer bipartisan legislation on behalf the state most affected by the virus. That too was rejected.

So it was no surprise that when I asked the Republican leader of the Senate to exercise his power to have the Senate take up and pass a stand-alone Zika-funding bill – and to keep the Senate in session if necessary to get it done – he declined.

The longer we wait for Congress to act, the more this virus will spread and the worse this problem will become.

In April, officials at the Centers for Disease Control and Prevention announced that the Zika virus is “scarier than we initially thought.” Two days later, the CDC confirmed that Zika does, in fact, cause microcephaly and other birth defects. And just last week, the first baby with Zika-related microcephaly was born here in the continental U.S.

As we head into these warmer summer months, the number of Americans infected with Zika will inevitably rise – especially in southern states such as Florida that will likely see a dramatic increase in the number of the Aedes aegypti mosquitoes capable of transmitting the virus.

Congress cannot simply sit back and rest its hopes on two bills likely to fail.

Our country is facing a serious threat and Congress must act immediately. Any further delay is simply unacceptable.

Sen. Nelson is Florida's senior U.S. senator and lead sponsor of the Senate bill to provide $1.9 billion to fight the Zika virus.

thehill.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (6883)6/6/2016 5:00:59 PM
From: donpat
   of 12856
 
And what are the chances that NanoViricides will receive one thin dime of that money?

None or nada??

First - do they want any??

If yes, how much?

And what will they do if they get any??

Business as usual and hope?

Or is there a plan in place with a course of action leading to a possible therapeutic drug - ZikaCide?????

As I understand the background, NanoViricides can whip up a drug to cure any virus (not Ebola!) in 4 - 6 weeks.

You'd think that would get the attention of the money givers.

It got MY attention way back when I first heard of it - some years ago:
We could have made a drug for the SARS virus in a few weeks using our technology. All I needed was the antibody. Essentially, it’s using the nanomicelle as a missile with the receptor mimic as the “guidance” system," the chief explains. “We should be able to plug in one mimic after another once our first drug hopefully gets approved by the FDA, with one drug expected to move into the approval stage every six months after the first one is completed." proactiveinvestors.com
"The rapid development and deployment capability of our platform technology was demonstrated by how quickly we were able to create these drug candidates," said Dr. Eugene Seymour, MD, MPH, Chief Executive Officer of the Company, explaining, "The design of a set of viable ligands was completed in merely three weeks, and the initial syntheses took another four weeks." nanoviricides.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (6884)6/6/2016 5:03:39 PM
From: donpat
   of 12856
 
In these circumstances, either I'm full of shit or the money givers are!

I don't see any other alternatives.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (6885)6/6/2016 5:06:59 PM
From: donpat
   of 12856
 
The Private Sector Is Stepping Up to Combat the Zika Virus—Congress Should Too

JUNE 6, 2016 AT 11:10 AM ET BY DR. TOM FRIEDEN

Summary:
Business leaders and philanthropic organizations are taking action to protect the American people.

Imagine this: You're standing by a lake and you see someone drowning. You have the ability to save that person, but your hands are tied.

Doctors who have spent the past three decades working in CDC’s birth defects center tell me that they have never seen a situation so urgent. The ability to prevent dozens, hundreds, or even thousands of severe birth defects creates a special responsibility – every child protected is a tragedy prevented.

The ongoing Zika outbreak poses a serious threat to pregnant women. It's been more than 50 years since we've seen a birth defect linked to a virus - and never before have we seen this result from a mosquito bite.

Make no mistake: The Zika virus is an emergency that we need to address. It will take all of us -- leaders in both the public and private sectors -- to ensure we mount a robust and comprehensive response in the United States.



There are things pregnant women can do to reduce the risk of Zika-related birth defects – including not traveling to areas where Zika is spreading or, for those who live in or must travel to such areas, taking steps to avoid mosquitoes. Men who have traveled to such areas and whose partners are pregnant should use condoms throughout the duration of the pregnancy.

The CDC Foundation, a nonprofit organization that builds private sector partnerships to help CDC protect more people, has been reaching out to business leaders and philanthropic organizations to help Americans protect themselves from the Zika virus. The response has been enthusiastic and generous.

For example, businesses have:

Donated bed nets, mosquito control tablets, and contraceptive technologies to support the CDC Foundation's contraception access effort in Puerto Rico.Supported the CDC Foundation's efforts to send Zika prevention kits to Puerto Rico to support pregnant women.Joined the Foundation in supporting a comprehensive health campaign to educate communities in the United States and territories, and empower women on how to prevent Zika transmission. You can see the full list of support the CDC Foundation is receiving from private sector leaders here.

They're doing their part, but the truth is that we just don't have the resources we need to protect our communities. The Department of Health and Human Services has already repurposed funding as a stopgap measure, and that's helping with immediate needs to expand lab capacity, develop diagnostic tests, and track infections in the United States and territories.

But that stopgap funding is just not enough to mount the robust response Americans deserve. The Zika response will take time and resources. The sooner we start on the hard work of better understanding, diagnosing, and preventing Zika, the sooner we will have better ways to protect pregnant women. That is why President Obama requested $1.9 billion in emergency funding from Congress back in February. Congress did the right thing with Ebola, and I am hopeful they will do the right thing with Zika.

Leaders in the private sector are not standing by. They're doing what they can to provide a life raft to those who are most at risk. My hope is that Congress will do the same -- and soon. When it comes to fighting an epidemic, every day counts.

Learn more: www.whitehouse.gov/zika

Dr. Tom Frieden is the Director of the Centers for Disease Control.

whitehouse.gov

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (6886)6/6/2016 5:12:03 PM
From: donpat
   of 12856
 
In re Zika - is the mosquito infected (does it get sick?) or just a carrier or both?

How is the mosquito infected? By ingesting the blood of an infected whatever - person or animal or whatever (bat, bird??)?

Share RecommendKeepReplyMark as Last Read


From: donpat6/6/2016 5:21:08 PM
   of 12856
 
Copper is key in burning fat: Scientist says results could provide new target for obesity research

June 6, 2016


Chris Chang and graduate student Sumin Lee carry out experiments to find proteins that bind to copper and potentially influence the storage and burning of fat. Credit: Peg Skorpinski/UC Berkeley

A new study is further burnishing copper's reputation as an essential nutrient for human physiology. A research team led by a scientist at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and at the University of California, Berkeley, has found that copper plays a key role in metabolizing fat.

Long prized as a malleable, conductive metal used in cookware, electronics, jewelry and plumbing, copper has been gaining increasing attention over the past decade for its role in certain biological functions. It has been known that copper is needed to form red blood cells, absorb iron, develop connective tissue and support the immune system.

The new findings, to appear in the July print issue of Nature Chemical Biology but published online today, establishes for the first time copper's role in fat metabolism.

The team of researchers was led by Chris Chang, a faculty scientist at Berkeley Lab's Chemical Sciences Division, a UC Berkeley professor of chemistry and a Howard Hughes Medical Institute investigator. Co-lead authors of the study are Lakshmi Krishnamoorthy and Joseph Cotruvo Jr, both UC Berkeley postdoctoral researchers in chemistry with affiliations at Berkeley Lab.

"We find that copper is essential for breaking down fat cells so that they can be used for energy," said Chang. "It acts as a regulator. The more copper there is, the more the fat is broken down. We think it would be worthwhile to study whether a deficiency in this nutrient could be linked to obesity and obesity-related diseases."

Dietary copper

Chang said that copper could potentially play a role in restoring a natural way to burn fat. The nutrient is plentiful in foods such as oysters and other shellfish, leafy greens, mushrooms, seeds, nuts and beans.

According to the Food and Nutrition Board of the Institute of Medicine, an adult's estimated average dietary requirement for copper is about 700 micrograms per day. The Food and Nutrition Board also found that only 25 percent of the U.S. population gets enough copper daily.

"Copper is not something the body can make, so we need to get it through our diet," said Chang. "The typical American diet, however, doesn't include many green leafy vegetables. Asian diets, for example, have more foods rich in copper."

But Chang cautions against ingesting copper supplements as a result of these study results. Too much copper can lead to imbalances with other essential minerals, including zinc.

Copper as a 'brake on a brake'

The researchers made the copper-fat link using mice with a genetic mutation that causes the accumulation of copper in the liver. Notably, these mice have larger than average deposits of fat compared with normal mice.


A fluorescent probe creates a heat map of copper in white fat cells. Higher levels of copper are shown in yellow and red. The left panel shows normal levels of copper from fat cells of control mice, and the right panel shows cells deficient … moreThe inherited condition, known as Wilson's disease, also occurs in humans and is potentially fatal if left untreated.

Analysis of the mice with Wilson's disease revealed that the abnormal buildup of copper was accompanied by lower than normal lipid levels in the liver compared with control groups of mice. The researchers also found that the white adipose tissue, or white fat, of the mice with Wilson's disease had lower levels of copper compared with the control mice and correspondingly higher levels of fat deposits.

They then treated the Wilson's disease mice with isoproterenol, a beta agonist known to induce lipolysis, the breakdown of fat into fatty acids, through the cyclic adenosine monophosphate (cAMP) signaling pathway. They noted that the mice with Wilson's disease exhibited less fat-breakdown activity compared with control mice.

The results prompted the researchers to conduct cell culture analyses to clarify the mechanism by which copper influences lipolysis. The researchers used inductively coupled plasma mass spectroscopy (ICP-MS) equipment at Berkeley Lab to measure levels of copper in fat tissue.

They found that copper binds to phosphodiesterase 3, or PDE3, an enzyme that binds to cAMP, halting cAMP's ability to facilitate the breakdown of fat.

"When copper binds phosphodiesterase, it's like a brake on a brake," said Chang. "That's why copper has a positive correlation with lipolysis."

Hints from cows

The connection between copper and fat metabolism is not altogether surprising. The researchers actually found hints of the link in the field of animal husbandry.

"It had been noted in cattle that levels of copper in the feed would affect how fatty the meat was," said Chang. "This effect on fat deposits in animals was in the agricultural literature, but it hadn't been clear what the biochemical mechanisms were linking copper and fat."

The new work builds upon prior research from Chang's lab on the roles of copper and other metals in neuroscience. In support of President Barack Obama's BRAIN Initiative, Berkeley Lab provided Chang seed funding in 2013 through the Laboratory Directed Research and Development program. Chang's work continued through the BRAIN Tri-Institutional Partnership, an alliance with Berkeley Lab, UC Berkeley and UC San Francisco.

Of the copper in human bodies, there are particularly high concentrations found in the brain. Recent studies, including those led by Chang, have found that copper helps brain cells communicate with each other by acting as a brake when it is time for neural signals to stop.

While Chang's initial focus was on the role of copper in neural communications, he branched out to investigations of metals in fat metabolism and other biological pathways. This latest work was primarily funded by the National Institutes of Health.

Explore further: Researchers developing unique molecular probes for the study of metals in the brain

More information: Lakshmi Krishnamoorthy et al, Copper regulates cyclic-AMP-dependent lipolysis, Nature Chemical Biology(2016). DOI: 10.1038/nchembio.2098

Journal reference: Nature Chemical Biology

Provided by: Lawrence Berkeley National Laboratory

Read more at: phys.org

Share RecommendKeepReplyMark as Last Read


From: Straynut6/7/2016 7:20:38 AM
   of 12856
 
NanoViricides to Present at the BIO2016 International Convention - on June 8, 2016, at 11a.m. Pacific Time NanoViricides, Inc.17 minutes ago


SHELTON, Conn., June 7, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a pioneer in developing nanomedicines that directly attack viruses using biomimicry, announced today that it will present at the BIO2016 International Convention on Wednesday June 8, 2016, in San Francisco, California.
View photo
.The presentation by the Company's CEO, Eugene Seymour, MD, MPH, is scheduled to begin at 11am and will report recent progress as well as explain the nature of the NanoViricides technology.
NanoViricides is actively developing topical antivirals against several different herpesvirus indications, namely, cold sores caused by HSV-1, genital ulcers caused by HSV-2, shingles caused by VZV (the chickenpox virus), and ocular herpes keratitis. The total market size for these indications is estimated to be several billions of dollars. The Company has previously shown complete survival in lethally infected animals with HSV-1 H129 strain infection. The H129 strain is derived from a clinical strain and is a highly infectious, neurotropic virus that causes very high morbidity. Since then the Company has been engaged in further drug optimization and process engineering developments necessary for performing manufacture under current Good Manufacturing Practices (cGMP). A cGMP product is needed for human clinical trials in the USA.
NanoViricides is one of very few small bio-pharma companies that possess their own pilot scale cGMP manufacturing facilities. NanoViricides believes this internal manufacturing capability helps in rapid progress to clinical trials for all of our novel, industry-leading nanomedicine drug candidates. Internal manufacturing also maximally protects our intellectual property. In addition, our multi-kilogram batch production capacity may allow market entry as a stand-alone pharmaceutical company while enabling early revenues, once a product is licensed.
NanoViricides is also working on developing a broad-spectrum nanoviricide to treat diseases caused by several flaviviruses. These flaviviruses include all four subtypes of dengue viruses, as well as the recent epidemic Zika virus, among others. There are no assurances that this work will lead to an effective drug in a rapid timeframe.
NanoViricides is also developing two broad-spectrum drugs to treat influenza virus infections, namely, Injectable FluCide™ for the treatment of severely ill, hospitalized patients, and Oral FluCide™ for the treatment of our-patients.
The presentation will be available on the Company website athttps://webmail.myfairpoint.net/hwebmail/services/go.php?url=http%3A%2F%2Fwww.nanoviricides.com%2Finvestorinfo.html.
About NanoViricides:
NanoViricides, Inc. ( www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Shingles, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

To view the original version on PR Newswire, visit:https://webmail.myfairpoint.net/hwebmail/services/go.php?url=http%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fnanoviricides-to-present-at-the-bio2016-international-convention---on-june-8-2016-at-11am-pacific-time-300280674.html

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Straynut who wrote (6889)6/7/2016 9:18:23 AM
From: donpat
1 Recommendation   of 12856
 
NanoViricides is also working on developing a broad-spectrum nanoviricide to treat diseases caused by several flaviviruses. These flaviviruses include all four subtypes of dengue viruses, as well as the recent epidemic Zika virus, among others. There are no assurances that this work will lead to an effective drug in a rapid timeframe.
Good - at least they are working on a Zika solution/cure/answer!!

A for effort.

SHOW ME THE MONEY$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (6890)6/7/2016 10:28:00 AM
From: drkaz
   of 12856
 
I am glad to see this being openly admitted,.... its something that I have thought they should be working on all Spring,.... and something that their new Virologist hire and the recently certified containment rooms at the Shelton facility are very clearly able to do.

They'll still have to do any animal testing with a contracted lab outside of Shelton, but they can do a lot of the early screening tests in Shelton and save both time and money.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10